Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, resulting in dramatic response in HPV (Human Papilloma Virus) virus related cancers of the throat. This trial will leverage targeted tumor radiation and immunotherapy in advance of standard surgical therapy to improve the response of HPV (Human Papilloma Virus) throat cancer to radiation and immunotherapy.

Trial Details

NCT ID
NCT05787639
Phase
PHASE2
Sponsor
University of California, San Diego
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Evorpacept
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Portland, Oregon, United States|45.52345,-122.67621
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Histologically confirmed diagnosis of Stage I T1-2N1M0 HPVOPC (Human Papilloma Virus Oropharynx Cancer)
  • Amenable to surgical resection
  • Are able to safely receive neoadjuvant radiation and Evorpacept/Pembrolizumab

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →